Clinical trials: Mask
Dry Eye
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber
- Trial name
- NCT05102409
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution)
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT07851259
- Testing
- RO7965032
- Where
- 5 sites in United States
- Volunteers
- 321 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Central Retinal Artery Occlusion
A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based therapy for CRAO.
- Trial name
- GION (NCT06178055)
- Testing
- KUS121 high dose, KUS121 low dose
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
Neovascular Age-Related Macular Degeneration
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD).
- Trial name
- PULSAR (NCT04423718)
- Testing
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Where
- 235 sites in United States, Argentina and 25 more
- Volunteers
- 1,011 people
- Sponsor
- Bayer
Dry Eye Disease
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05759208
- Testing
- OK-101
- Where
- 6 sites in United States
- Volunteers
- 240 people
- Sponsor
- Okyo Pharma Ltd
Respiratory Failure, Covid19
Mask Adhesive Institutional Study
To reduce interface leak and aerosol spread, Philips has developed an accessory to non-invasive ventilation(NIV) masks to be used with the Philips AF531 and the PerformaTrak mask on respiratory failure patients.
- Trial name
- NCT04644276
- Testing
- Mask with Mask Adhesive/Arm 1, Mask without Mask Adhesive / Arm 2
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
"Wet" Age-Related Macular Degeneration
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00139282
- Testing
- Squalamine Lactate
- Where
- 29 sites in United States
- Sponsor
- Genaera Corporation
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Retinitis Pigmentosa
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)
Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with…
- Trial name
- NCT05841862
- Testing
- 2C-QD
- Sponsor
- 2C Tech Corp
Patient Ventilator Interactions
Analysis and Evaluation of Asynchronies Between NIV Patients and Their Prisma VENT or LUISA Ventilator
This study aims to analyze the types, rates, and patterns of disturbances between the breathing of patients receiving non-invasive ventilation and their ventilator (patient-ventilator asynchronies, PVA) during routine therapy…
- Trial name
- NCT07768748
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- Löwenstein Medical Technology GmbH & Co. KG
Ocular Hypertension, Open Angle Glaucoma
Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma
The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure…
- Trial name
- NCT00443924
- Testing
- INS115644 Ophthalmic Solution
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye Due to Sjögren's Syndrome
Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome
Dry eye complaints occur in 5.5 to 33.7% of the population, and are ranked as the most frequent symptoms of patients visiting ophthalmologists.
- Trial name
- NCT03319420
- Testing
- LO2A eye drops, Systane Ultra UD
- Where
- 5 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Ocuwize LTD
Ocular Hypertension, Open-Angle Glaucoma
A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma
Determine efficacy of the latanoprost punctal plug. Effect of configuration of L-PPDS placement on efficacy will also be examined.
- Trial name
- NCT02014142
- Testing
- Latanoprost Punctal Plug Delivery System (L-PPDS)
- Where
- 18 sites in United States
- Volunteers
- 86 people
- Sponsor
- Mati Therapeutics Inc.
Amblyopia
Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia
The purpose of this PoC study was to evaluate the potential therapeutic efficacy of binocular video games played on a tablet and to compare the efficacy of binocular video games versus patching in amblyopic patients 4 to 7 years…
- Trial name
- NCT04784390
- Testing
- Binocular video games, Patching of the sound eye
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Aniridia
Study of Ataluren in Participants With Nonsense Mutation Aniridia
This study is designed to evaluate the effect of ataluren on Maximum Reading Speed as measured using the Minnesota Low Vision Reading Test (MNREAD) Acuity Charts in participants with nonsense mutation aniridia.
- Trial name
- STAR (NCT02647359)
- Testing
- Ataluren
- Where
- 3 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- PTC Therapeutics
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W)…
- Trial name
- NCT03622580
- Testing
- Aflibercept, Faricimab
- Where
- 185 sites in United States, Austria and 14 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.